Edition:
United States

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

488.90INR
26 May 2017
Change (% chg)

Rs-15.10 (-3.00%)
Prev Close
Rs504.00
Open
Rs483.00
Day's High
Rs504.75
Day's Low
Rs480.20
Volume
7,010,307
Avg. Vol
1,266,963
52-wk High
Rs621.25
52-wk Low
Rs459.00

Select another date:

Thu, May 25 2017

India's Cipla lowers bio drugs investment, sharpens focus on respiratory

MUMBAI Cipla Ltd , India's fifth-largest drugmaker by sales, plans to reduce investment in biosimilars to sharpen its focus on building a portfolio of high-margin respiratory products, the company's chief executive said on Thursday.

UPDATE 1-India's Cipla lowers bio drugs investment, sharpens focus on respiratory

* Posts Q4 loss vs. analysts' forecast for profit (Recasts with CEO's comments)

Indian drugmaker Cipla narrows loss in Jan-March, misses forecasts

MUMBAI, May 25 Cipla Ltd, India's fifth-largest drugmaker by sales, reported a smaller quarterly loss for January-March, but missed expectations of a profit for the period.

BRIEF-India's Cipla March-qtr loss narrows

* Consol march quarter total income from operations 35.82 billion rupees

BRIEF-Cipla U.S. arm signs worldwide licensing deal with MEDRx

* Medrx is eligible to receive up to USD 30 million cumulatively through upfront and developmental, regulatory, and commercial milestones payments

BRIEF-Cipla launches Hepatitis B vaccine in India

* Says Cipla launches Hepatitis B vaccine in India Source text - (http://bit.ly/2lUwkV6) Further company coverage:

BRIEF-Cipla Ltd Dec-qtr consol profit up about 44 pct

* Consol net profit in Dec quarter last year was 2.61 billion rupees as per Ind-AS; consol net sales was 30.70 billion rupees

India's Cipla Q3 profit up 43.7 pct, tops estimates

MUMBAI, Feb 8 Indian drugmaker Cipla Ltd reported a 43.7 percent jump in third-quarter net profit, beating analysts' expectations.

Select another date:

More From Around the Web